Repositioning of Tamoxifen in Surface-Modified Nanocapsules as a Promising Oral Treatment for Visceral Leishmaniasis

Standards of care for human visceral leishmaniasis (VL) are based on drugs used parenterally, and oral treatment options are urgently needed. In the present study, a repurposing strategy was used associating tamoxifen (TMX) with polyethylene glycol-block-polylactide nanocapsules (NC) and its anti-le...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics Vol. 13; no. 7; p. 1061
Main Authors: Silva, Débora Faria, Reis, Levi Eduardo Soares, Machado, Marina Guimarães Carvalho, Dophine, Douglas Daniel, de Andrade, Vinicius Roberto, de Lima, Wanderson Geraldo, Andrade, Margareth Spangler, Vilela, José Mário Carneiro, Reis, Alexandre Barbosa, Pound-Lana, Gwenaelle, Rezende, Simone Aparecida, Mosqueira, Vanessa Carla Furtado
Format: Journal Article
Language:English
Published: Basel MDPI AG 10-07-2021
MDPI
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Standards of care for human visceral leishmaniasis (VL) are based on drugs used parenterally, and oral treatment options are urgently needed. In the present study, a repurposing strategy was used associating tamoxifen (TMX) with polyethylene glycol-block-polylactide nanocapsules (NC) and its anti-leishmanial efficacy was reported in vivo. Stable surface modified-NC (5 mg/mL of TMX) exhibited 200 nm in size, +42 mV of zeta potential, and 98% encapsulation efficiency. Atomic force microscopy evidenced core-shell-NC. Treatment with TMX-NC reduced parasite-DNA quantified in liver and spleen compared to free-TMX; and provided a similar reduction of parasite burden compared with meglumine antimoniate in mice and hamster models. Image-guided biodistribution showed accumulation of NC in liver and spleen after 30 min post-administration. TMX-NC reduced the number of liver granulomas and restored the aspect of capsules and trabeculae in the spleen of infected animals. TMX-NC was tested for the first time against VL models, indicating a promising formulation for oral treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13071061